靶向ERBB2在转移性结直肠癌治疗中的研究进展  

Advances in the study of ERBB2 in the treatment of metastatic colorectal cancer

作　　者：王科[1] 苏国庆 钱靖航 朱羽 杨柳[1] WANG Ke;SU Guoqing;QIAN Jinghang;ZHU Yu;YANG Liu(Department of colorectal surgery,The Affiliated Cancer Hospital of Nanjing Medical University&Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research,Nanjing 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院/江苏省肿瘤医院/江苏省肿瘤防治研究所普外科,江苏南京210009

出　　处：《中国肿瘤外科杂志》2025年第1期98-104,共7页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金(81602145,82072704)。

摘　　要：结直肠癌(CRC)是全球第三大常见的恶性肿瘤,也是全球癌症相关死亡的第二大原因。尽管近些年在恶性肿瘤的综合治疗方面有所改进,但转移性结直肠癌(mCRC)的预后仍然较差。值得注意的是,5%的mCRC病例中存在Erb-B2受体酪氨酸激酶2(ERBB2)的改变。ERBB2通常被称为人类表皮生长因子受体2,是人类表皮生长因子受体家族的成员,属于蛋白酪氨酸激酶。除了在胃癌和乳腺癌治疗中被公认为治疗靶点外,它在结直肠癌的管理中也被认为是至关重要的。该综述从mCRC靶向治疗的生物标志物的角度描述了ERBB2的分子生物学,新的靶向治疗方法和正在进行的临床试验。这可能有助于为ERBB2阳性mCRC患者制定新的治疗标准。Colorectal cancer(CRC)is the third most common malignant tumor worldwide and the second leading cause of cancer-related deaths globally.Despite recent improvements in the comprehensive treatment of malignant tumors,the prognosis for metastatic colorectal cancer(mCRC)remains poor.Notably,5%of mCRC cases exhibit alterations in the Erb-B2 receptor tyrosine kinase 2(ERBB2).ERBB2,commonly known as human epidermal growth factor receptor 2,is a member of the human epidermal growth factor receptor family and belongs to the protein tyrosine kinase class.In addition to being recognized as a therapeutic target in the treatment of gastric and breast cancer,it is also considered crucial in the management of colorectal cancer.In this review,we describe the molecular biology of ERBB2 from the perspective of biomarkers for targeted therapy in mCRC,new targeted treatment methods,and ongoing clinical trials.This may help to establish new treatment standards for patients with ERBB2-positive mCRC.

关 键 词：ERBB2 结直肠癌 靶向治疗 研究进展 

分 类 号：R735.34[医药卫生—肿瘤]